NIAID conducts and supports research to better understand, treat, and ultimately prevent infectious and immune-mediated diseases. For more than 60 years, NIAID research has led to new therapies, vaccines, diagnostic tests, and other technologies that have improved the health of millions of people in the United States and abroad. This page highlights notable scientific advances made by NIAID laboratories and NIAID-funded researchers.
In April 2013, NIAID-funded researchers at the Duke University Human Vaccine Institute reported the isolation of a naturally occurring, broadly neutralizing antibody (BnAb) called CH103. Remarkably, the scientists were able to track the evolution of both the antibody and HIV over the course of the patient's infection.
In January 2013, NIAID researchers and their colleagues successfully completed a Phase I clinical trial of a group of dengue vaccine candidates developed in NIAID labs. They selected one candidate, called TV003, for a Phase II trial. Among the vaccines tested, TV003 induced the most balanced antibody response against the four human dengue virus types. In 90 percent of vaccine recipients, a single dose of TV003 induced immune responses against three or more viruses. Because it requires only a single dose, TV003 may be less expensive to produce in dengue-endemic regions such as South America and Asia.
H7N9 is an emerging avian influenza virus, with the earliest human case reported in Shanghai, China, in March 2013. By April 2013, NIAID-funded investigators sequenced important genes from samples isolated from four patients in three Chinese cities.
Read more Selected NIAID Research Advances of 2013.
Decades of NIAID-funded research helped create FluMist, the first nasal spray vaccine for influenza approved by the Food and Drug Administration.
NIAID research on mother-to-child transmission of HIV has paved the way for new health interventions that have saved lives in the United States and abroad.
NIAID scientists played a crucial role in the development of Havrix, the world’s first licensed hepatitis A vaccine.
Read more Selected Historical NIAID Research Advances.
NIAID Years in Review highlight the Institute's programmatic and scientific accomplishments and describe how its budget is distributed. They also celebrate the accomplishments of NIAID-funded investigators.
Last Updated June 09, 2014